The Role of Maintenance Therapy in Today's Myeloma: Has Anything Changed?
Recorded on May 22nd, 2024 as part of the Relapsed/Refractory Myeloma Group in the Educational Webinar Program by HealthTree with Dr. Sam Rubenstein. The HealthTree Foundation for Multiple Myeloma brings information from the experts to the patients! Learn more at https://www.healthtree.org/myeloma/co... Donate to the HealthTree Foundation for Multiple Myeloma or learn more about additional myeloma support we offer here: https://give.healthtree.org/campaign/... HealthTree Cure Hub helps you find your best treatment options and accelerate a cure for multiple myeloma. Join today at https://www.healthtree.org/ Follow HealthTree: twitter.com/healthtreeformm facebook.com/healthtreeformultiplemyeloma instragram.com/healthtreeformultiplemyeloma
Talquetamab Side Effect Management
Recent Advances in Multiple Myeloma with Dr. Dan Vogl
The Lenalidomide Patch for Myeloma: What Do We Know?
The Question of Maintenance Therapy: For Whom and How Long?
Myths vs. Facts about Diet in Multiple Myeloma
What do tech pioneers think about the AI revolution? - The Engineers, BBC World Service
Will the Smoldering Myeloma Diagnosis Phase Out?
What caused my IPMN... RESULTS!
Game-Changing Therapy in Relapsed and Refractory Myeloma | Ajay Nooka, MD #myeloma
Myeloma 101: Understanding Multiple Myeloma, Risk Factors, Diagnosis & Treatments Explained
Innovations in Myeloma Therapies: Promise of ADCs, CELMoDs, BCL2 Inhibitors, & SINEs | Dan Vogl, MD
FAQs: Immunotherapy for Multiple Myeloma: Exploring Options Through Your Disease Journey
Why Can’t We Cure Cancer? A National Conversation | Full CUOMO Special Edition 2/27
028 Myeloma in 2026 - What's Coming Next and Why It Matters
Sequencing BCMA Myeloma Therapies
Learn more about THYROID RFA: Dr. Jules Aljammal - #80
How Personalized Is Myeloma Treatment and How Is Changing? Introducing the Individual Risk Model
What Is Multiple Myeloma? A Simple Guide for Newly Diagnosed
Recognizing Post-Viral Syndromes & Tools for Management
